On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's unique rating measures share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they begin their largest climbs.
See How IBD Helps You Make More Money In Stocks
Is BioCryst Pharmaceuticals Stock A Buy?
BioCryst Pharmaceuticals stock is trying to complete a consolidation with a 15.53 buy point. See if the stock can break out in heavy trade.
The biotech company posted -33% earnings growth in the latest quarterly report. Revenue rose 31%. The company is expected to report its latest numbers on or around Nov. 3.
BioCryst Pharmaceuticals stock earns the No. 96 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharma, Vertex Pharmaceuticals and Genmab are among the top 5 highly rated stocks within the group. For more industry news, check out "
Biotech And Pharmaceutical Industry And Stock News."
